Atopic dermatitis: The updated practice parameter and beyond

Allergy and Asthma Proceedings

Volumn 35, Issue 6, 2014, Pages 429-434

  Mark, Boguniewicz ^a  

^a Children's Hospital Colorado   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; BLEACHING AGENT; CALCINEURIN INHIBITOR; CELL PENETRATING PEPTIDE; CORTICOSTEROID; CYCLOSPORIN; CYTOKERATIN 10; DUPILUMAB; FILAGGRIN; FLUTICASONE; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR ALPHA; LORICRIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; N (4 AMINO 2 METHYL 6 QUINOLINYL) 2 (4 ETHYLPHENOXYMETHYL)BENZAMIDE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 1; PSEUDOMONIC ACID; STEROID; TACROLIMUS; UNCLASSIFIED DRUG; ANTIALLERGIC AGENT;

ALGORITHM; ARTICLE; ATOPIC DERMATITIS; CELL DIFFERENTIATION; DERMATITIS; DISEASE SEVERITY; ECZEMA; EXPERIMENTAL THERAPY; FOLLICULITIS; HUMAN; IMMUNE DYSREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; KERATINOCYTE; MAINTENANCE THERAPY; MONOTHERAPY; NONHUMAN; NURSING EDUCATION; PROTEIN EXPRESSION; QUALITY OF LIFE; RELAPSE; SCRATCHING; SKIN INFECTION; SKIN MACERATION; SLEEP; SOCIAL PSYCHOLOGY; DERMATITIS, ATOPIC; DISEASE MANAGEMENT; PHYSIOTHERAPY;

ANTI-ALLERGIC AGENTS; DERMATITIS, ATOPIC; DISEASE MANAGEMENT; HUMANS; PHYSICAL THERAPY MODALITIES;

EID: 84910606207     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2014.35.3798     Document Type: Article

References (32)

1. Boguniewicz M, and Leung DY. Atopic dermatitis: A disease of altered skin barrier and immune dysregulation. Immunol Rev 242:233-246, 2011.
2. Shaw TE, Currie GP, Koudelka CW, and Simpson EL. Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health. J Invest Dermatol 131:67-73, 2011.
3. Odhiambo JA, Williams HC, Clayton TO, et al. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol 124:1251-1258.e23, 2009.
4. DaVeiga SP. Epidemiology of atopic dermatitis: A review. Allergy Asthma Proc 33:227-234, 2012.
5. Margolis JS, Abuabara K, Bilker W, et al. Persistence of mild to moderate atopic dermatitis. JAMA Dermatol 150:593-600, 2014.
6. Schneider L, Tilles S, Lio P, et al. Atopic dermatitis: A practice parameter update 2012. J Allergy Clin Immunol 131:295-299, 2013.
7. Leung DY, Nicklas RA, Li JT, et al. Disease management of atopic dermatitis: An updated practice parameter. Joint Task Force on Practice Parameters. Ann Allergy Asthma Immunol 93:S1-S21, 2004.
8. McAleer MA, and Irvine AD. The multifunctional role of filaggrin in allergic skin disease. NOT J Allergy Clin Immunol 131:280- DO 291, 2013.
9. Henderson J, Northstone K, Lee SP, et al. The burden of disease associated with filaggrin mutations: A population-based, longitudinal birth cohort study. J Allergy Clin Immunol 121:872-877.e9, 2008.
10. Irvine AD, McLean WH, and Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med 365: 1315-1327, 2011.
11. Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol 120:150-155, 2007.
12. Zuberbier T, Orlow SJ, Paller AS, et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol 118:226-232, 2006.
13. Kojima R, Fujiwara T, Matsuda A, et al. Factors associated with steroid phobia in caregivers of children with atopic dermatitis. Pediatr Dermatol 30:29-35, 2013.
14. Arellano FM, Wentworth CE, Arana A, et al. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 127:808-816, 2007.
15. Fonacier L, Spergel J, Charlesworth EN, et al.; American College of Allergy, Asthma and Immunology; American Academy of Allergy, Asthma and Immunology. Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 115:1249-1253, 2005.
16. Huang JT, Abrams M, Tlougan B, et al. Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics 123:e808-e814, 2009. COPY
17. Ong PY. Association between egg and staphylococcal superantigen IgE sensitizations in atopic dermatitis. Allergy Asthma Proc 35:346-348, 2014.
18. Boyce JA, Assa'ad A, Burks AW, et al.; NIAID-Sponsored Expert Panel. Guidelines for the diagnosis and management of food allergy in the United States: Summary of the NIAIDSponsored Expert Panel Report. J Allergy Clin Immunol 126: 1105-1118, 2010.
19. Fleischer DM, Bock SA, Spears GC, et al. Oral food challenges in children with a diagnosis of food allergy. J Pediatr 158:578- 583.e1, 2011.
20. Bergmann MM, Caubet JC, Boguniewicz M, et al. Evaluation of food allergy in patients with atopic dermatitis. J Allergy Clin Immunol Pract 1:22-28, 2013.
21. Hamid Q, Boguniewicz M, and Leung DY. Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest 94:870-876, 1994.
22. Suarez-Farinas M, Tintle SJ, Shemer A, et al. Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J Allergy Clin Immunol 127:954 -964.e1- 4, 2011.
23. Schmitt J, von Kobyletzki L, Svensson A, and Apfelbacher C. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: Systematic review and meta-analysis of randomized controlled trials. Br J Dermatol 164:415-428, 2011.
24. Healy E, Bentley A, Fidler C, and Chambers C. Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: Twice-weekly maintenance treatment vs. standard twice-daily reactive treatment of exacerbations from a third party payer (U.K. National Health Service) perspective. Br J Dermatol 164:387-395, 2011.
25. Boguniewicz M, and Leung DY. The ABC's of managing patients with severe atopic dermatitis. J Allergy Clin Immunol 132:511-512.e5, 2013.
26. Boguniewicz M, Nicol N, Kelsay K, and Leung DY. A multidisciplinary approach to evaluation and treatment of atopic dermatitis. Semin Cutan Med Surg 27:115-127, 2008.
27. Nicol NH, Boguniewicz M, Strand M, and Klinnert MD. Wet wrap therapy in children with moderate to severe atopic dermatitis in a multidisciplinary treatment program. J Allergy Clin Immunol Pract 2:400-406, 2014.
28. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: A practice parameter third update. J Allergy Clin Immunol 127: S1-S55, 2011.
29. Otsuka A, Doi H, Egawa G, et al. Possible new therapeutic strategy to regulate atopic dermatitis through upregulating filaggrin expression. J Allergy Clin Immunol 133:139 -146.e1-10, 2014.
30. Stout TE, McFarland T, Mitchell JC, et al. Recombinant filaggrin is internalized and processed to correct filaggrin deficiency. J Invest Dermatol 134:423-429, 2014.
31. Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 368:2455-2466, 2013.
32. Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 371:130-139, 2014. e